Abstract
Structure-based drug design (SBDD) is an important technique in computer-aided drug design, which utilises structural information of a targeted protein to elucidate novel drug-like compounds. This rapidly advancing technique has bought new breakthroughs in the pharmaceutical industry. Burgeoning structural information on proteins and small molecules has provided the scientific community with many new drug targets and novel opportunities for future drug discovery. This article provides a comprehensive overview of the current status of in silico SBDD and discusses the current challenges and limitations. Key strategies in the field of SBDD will be illustrated through a case study that explores the design of anti-malarial drugs targeting Plasmodium falciparum hemoglobin degrading enzyme Plasmepsin II.
Original language | English |
---|---|
Title of host publication | Encyclopedia of bioinformatics and computational biology |
Subtitle of host publication | ABC of Bioinformatics |
Editors | Shoba Ranganathan, Michael Gribskov, Kenta Nakai, Christian Schönbach |
Place of Publication | Amsterdam |
Publisher | Elsevier |
Pages | 585-600 |
Number of pages | 16 |
Volume | 2 |
ISBN (Electronic) | 9780128114322 |
ISBN (Print) | 9780128114148 |
DOIs | |
Publication status | Published - 2019 |
Keywords
- Computational aided drug design
- De novo design
- Focused library design
- High-throughput virtual screening
- Malaria
- Molecular docking
- Plasmepsin ii
- Protein modeling
- Structure-based drug design
- Target selection